• Simris Group’s third-quarter operating loss widened 8% to SEK 7.73 million; net revenue fell 51% to SEK 236,000.
• January–September operating loss narrowed 11% to SEK 18.79 million; net revenue dropped 36% to SEK 856,000.
• Warrant exercises generated EUR 1.02 million in proceeds, fully paid and registered in October 2026.
• The group confirmed plans to advance two amanitin-based antibody-drug conjugate programs toward clinical development.
• Simris mutually agreed with Lonza in October to void their exclusive technology agreement to expand its flexibility in choosing partners.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simris Group AB published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.